Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis

被引:109
作者
Blair, JM [1 ]
Zhou, H [1 ]
Seibel, MJ [1 ]
Dunstan, CR [1 ]
机构
[1] Univ Sydney, Bone Res Program, ANZAC Res Inst, Sydney, NSW 2139, Australia
来源
NATURE CLINICAL PRACTICE ONCOLOGY | 2006年 / 3卷 / 01期
关键词
D O I
10.1038/ncponc0381
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The discovery of osteoprotegerin, receptor activator of nuclear factor kappa B (RANK) and RANK ligand as critical molecular determinants of osteoclastogenesis and regulators of bone resorption, has revolutionized our understanding of the processes of normal and pathological bone biology. Altering the relative biological availabilities of these molecules has direct consequences for the regulation of both bone resorption and bone remodeling. Importantly, recent research suggests a pivotal role for these molecules in mediating cancer-induced bone destruction. This review summarizes the current evidence of osteoprotegerin, RANK ligand RANK involvement in the pathophysiology of skeletal metastasis, and of therapeutic targeting of this process.
引用
收藏
页码:41 / 49
页数:9
相关论文
共 80 条
[1]
Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy [J].
Akatsu, T ;
Murakami, T ;
Ono, K ;
Nishikawa, M ;
Tsuda, E ;
Mochizuki, SI ;
Fujise, N ;
Higashio, K ;
Motoyoshi, K ;
Yamamoto, M ;
Nagata, N .
BONE, 1998, 23 (06) :495-498
[2]
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].
Anderson, DM ;
Maraskovsky, E ;
Billingsley, WL ;
Dougall, WC ;
Tometsko, ME ;
Roux, ER ;
Teepe, MC ;
DuBose, RF ;
Cosman, D ;
Galibert, L .
NATURE, 1997, 390 (6656) :175-179
[3]
Expression of osteoclast differentiation signals by stromal elements of giant cell tumors [J].
Atkins, GJ ;
Haynes, DR ;
Graves, SE ;
Evdokiou, A ;
Hay, S ;
Bouralexis, S ;
Findlay, DM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (04) :640-649
[4]
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].
Bekker, PJ ;
Holloway, DL ;
Rasmussen, AS ;
Murphy, R ;
Martin, SW ;
Leese, PT ;
Holmes, GB ;
Dunstan, CR ;
DePaoli, AM .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066
[5]
Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease [J].
Bendre, MS ;
Montague, DC ;
Peery, T ;
Akel, NS ;
Gaddy, D ;
Suva, LJ .
BONE, 2003, 33 (01) :28-37
[6]
Bhatia P, 2005, CLIN CANCER RES, V11, P162
[7]
BODY JJ, 2003, CANCER S, V97, pS887
[8]
Brown JM, 2001, CLIN CANCER RES, V7, P2977
[9]
Osteoprotegerin and rank ligand expression in prostate cancer [J].
Brown, JM ;
Corey, E ;
Lee, ZD ;
True, LD ;
Yun, TJ ;
Tondravi, M ;
Vessella, RL .
UROLOGY, 2001, 57 (04) :611-616
[10]
BROWN JM, 2004, BIOL SKELETAL METAST, P149